Vivet Therapeutics
PrivateLast Round
Grant
Feb 1, 2024
Est. Valuation
$340M
Total Funding Raised
$97.36M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Vivet Therapeutics is a biotechnology company that develops novel gene therapy treatments for rare, inherited metabolic diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Vivet Therapeutics Comparables
Compare Vivet Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 83% | |
| Genespire | 78% | |
| GEMMA Biotherapeutics | 75% |
Vivet Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Feb 1, 2024 | ||||
| Strategic | Mar 20, 2019 | ||||
| Series A | May 4, 2017 |
Key People
Founding team and executive leadership
Vivet Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Roche Venture Fund | Series A |
| Idinvest Partners | Series A |
| Ysios Capital | Series A |
| CVJ | Strategic |
| HealthCap | Series A |
| Roche Venture Fund | Series A |
| Pfizer | Strategic |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors increased 32% MoM to 5.9K.
- Apr 22, 2026
Monthly visitors increased 61% MoM.
Vivet Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Vivet Therapeutics's valuation, stock price, and market status.
Is Vivet Therapeutics a public or private company?
Vivet Therapeutics is a private company.
What is the current stock price of Vivet Therapeutics?
Vivet Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Vivet Therapeutics worth (valuation)?
Vivet Therapeutics's valuation is estimated at $340.0M based on funding round data.
Can I buy Vivet Therapeutics stock?
Vivet Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Vivet Therapeutics's last funding round?
Vivet Therapeutics's most recent funding round was Grant on March 20, 2019.
Who are the main investors in Vivet Therapeutics?
Key investors in Vivet Therapeutics include Bpifrance, Pfizer, Columbus Venture Partners.
Will Vivet Therapeutics IPO soon?
No public IPO plans have been announced for Vivet Therapeutics.
How can I track Vivet Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Vivet Therapeutics's secondary market activity and sign up for updates.